In a secondary analysis of a double-blind , placebo-controlled trial in which early post-menopausal women ( N = @ ) with normal bone density or osteopenia were randomized to infusion of zoledronate @ mg ( N = @ ) or placebo ( N = @ ) , we analyzed significant adverse ocular events occurring within @ months .